SCHEMBL16296557

SCHEMBL16296557

CC(C)(C)OC(=O)Cc1ccc(-n2cccn2)cc1-n1cccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 1/20 0.42
▸ LMNA P02545 2/20 0.39
▸ CHRM1 P11229 1/20 0.38
▸ PIK3CD O00329 1/20 0.37
▸ PIK3CA P42336 1/20 0.37
▸ PIK3CB P42338 1/20 0.37
▸ PIK3CG P48736 1/20 0.37
▸ MTNR1A P48039 2/20 0.37
▸ MTNR1B P49286 2/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ G6PD P11413 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ GLS O94925 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15157052 0.85 NPBWR1 (0.40) GPR119LMNACHRM1MTNR1AMTNR1B
SCHEMBL20681395 0.74 GPR119 (0.38) GPR119LMNARXFP1TP53
SCHEMBL6163346 0.74 KAT6A (0.47) GPR119LMNARXFP1KDM4EALDH1A1
SCHEMBL21988746 0.71 HCRTR1 (0.39) GPR119LMNAKDM4EALDH1A1MEN1
SCHEMBL22044792 0.71 PSEN1 (0.41) LMNAKDM4EALDH1A1MEN1MAPT
SCHEMBL27519236 0.71 KAT6A (0.48) GPR119LMNARXFP1KDM4EALDH1A1
SCHEMBL1316699 0.71 GPR119 (0.43) GPR119LMNARXFP1KDM4EALDH1A1
SCHEMBL22911215 0.70 GPR119 (0.55) GPR119LMNAPIK3CDALDH1A1MAPT
SCHEMBL29639974 0.70 GPR119 (0.55) GPR119LMNAPIK3CDALDH1A1MAPT
SCHEMBL3869870 0.69 GPR119 (0.49) GPR119CHRM1PIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2809668-B1 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2017-04-12 — — EP disclosed
US-9266876-B2 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2016-02-23 — — US disclosed
US-20140371204-A1 4-(Benzoimidazol-2-yl)-thiazole Compounds and Related Aza Derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2014-12-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371204-A1 4-(Benzoimidazol-2-yl)-thiazole Compounds and Related Aza Derivatives CXCR3, CXCR1, CXCR2 GPR119 234/4885LMNA 4684/4885CHRM1 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback